Sarah Sammons, Co-Director Breast Cancer Research and Treatment Program at University of Maryland Medical System, shared Sara Tolaney’s post on X, adding:
“These results are absolutely astounding.
This should give us enthusiasm to study more IT targeted therapies. I do need to understand in this trial who got concurrent TDxd as this is likely contributing to results.”
Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, shared:
“IT trastuzumab and pertuzumab for HER2+ LMD (Pts could continue treatment with HER2-directed systemic therapy)”
You can also read:
25 Posts Not to Miss from ESMO Congress 2026: Day 3
